Author: Kim, S. S.; Chung, J. R.; Belongia, E. A.; McLean, H. Q.; King, J. P.; Nowalk, M. P.; Zimmerman, R. K.; Balasubramani, G. K.; Martin, E. T.; Monto, A. S.; Lamerato, L. E.; Gaglani, M.; Smith, M. E.; Dunnigan, K. M.; Jackson, M. L.; Jackson, L. A.; Tenforde, M. W.; Verani, J. R.; Kobayashi, M.; Schrag, S.; Patel, M. M.; Flannery, B.
Title: mRNA Vaccine Effectiveness against COVID-19 among Symptomatic Outpatients Aged >=16 Years in the United States, February to May 2021 Cord-id: ad58qbqi Document date: 2021_7_22
ID: ad58qbqi
Snippet: Evaluations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged [≥]16 years, VE of mRNA vaccines against COVID-19 was 91% (95%
Document: Evaluations of vaccine effectiveness (VE) are important to monitor as COVID-19 vaccines are introduced in the general population. Research staff enrolled symptomatic participants seeking outpatient medical care for COVID-19-like illness or SARS-CoV-2 testing from a multisite network. VE was evaluated using the test-negative design. Among 236 SARS-CoV-2 nucleic acid amplification test-positive and 576 test-negative participants aged [≥]16 years, VE of mRNA vaccines against COVID-19 was 91% (95% CI: 83-95) for full vaccination and 75% (95% CI: 55-87) for partial vaccination. Vaccination was associated with prevention of most COVID-19 cases among people seeking outpatient medical care.
Search related documents:
Co phrase search for related documents- acip recommendation and acute illness experience: 1
- acip recommendation and adolescent adult: 1
- active surveillance and acute illness: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- active surveillance and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
- active surveillance and lung disease: 1, 2, 3, 4
- active surveillance network and logistic regression: 1
- acute illness and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute illness and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- acute illness experience and logistic regression: 1
- acute onset and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute onset and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- additional covariate and logistic regression: 1
- adolescent adult and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9
- adolescent adult and lung disease: 1, 2
- adolescent young adult and logistic regression: 1
- logistic regression and lung disease: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
Co phrase search for related documents, hyperlinks ordered by date